ATE303437T1 - Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren - Google Patents

Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren

Info

Publication number
ATE303437T1
ATE303437T1 AT97901343T AT97901343T ATE303437T1 AT E303437 T1 ATE303437 T1 AT E303437T1 AT 97901343 T AT97901343 T AT 97901343T AT 97901343 T AT97901343 T AT 97901343T AT E303437 T1 ATE303437 T1 AT E303437T1
Authority
AT
Austria
Prior art keywords
protein
methods
receptor
nucleic acids
receptors
Prior art date
Application number
AT97901343T
Other languages
English (en)
Inventor
Ming-Shi Chang
Andrew Avery Welcher
Frederick Addison Fletcher
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE303437T1 publication Critical patent/ATE303437T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97901343T 1996-01-04 1997-01-02 Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren ATE303437T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58282596A 1996-01-04 1996-01-04
US77441496A 1996-12-31 1996-12-31
PCT/US1997/000128 WO1997025424A1 (en) 1996-01-04 1997-01-02 Ob protein receptor and related compositions and methods

Publications (1)

Publication Number Publication Date
ATE303437T1 true ATE303437T1 (de) 2005-09-15

Family

ID=27078678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901343T ATE303437T1 (de) 1996-01-04 1997-01-02 Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren

Country Status (11)

Country Link
EP (1) EP0877803B1 (de)
JP (1) JP2000502569A (de)
AT (1) ATE303437T1 (de)
AU (1) AU1526297A (de)
DE (1) DE69734096T2 (de)
DK (1) DK0877803T3 (de)
ES (1) ES2244990T3 (de)
IL (1) IL125081A (de)
NZ (1) NZ534416A (de)
PT (1) PT877803E (de)
WO (1) WO1997025424A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
AU2476301A (en) * 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7084252B1 (en) 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7148004B1 (en) 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7619079B2 (en) 1996-02-14 2009-11-17 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
EP0921820A4 (de) * 1996-06-20 2003-01-15 Merck & Co Inc Genterapie für die fettleibigkeit
WO1998057177A1 (en) * 1997-06-09 1998-12-17 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents
US20020192751A1 (en) 1998-05-15 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6770444B2 (en) 1998-07-16 2004-08-03 Synaptic Pharmaceutical Corporation Methods of identifying or screening for agents that binds the Ob-Re
FR2836475B1 (fr) * 2002-02-26 2007-02-23 Aventis Pharma Sa Procede de detection de ligands du recepteur de la leptine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
DE69734443T2 (de) * 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
ATE320479T1 (de) * 1996-01-23 2006-04-15 Indevus Pharmaceuticals Inc Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen

Also Published As

Publication number Publication date
DE69734096T2 (de) 2006-06-29
NZ534416A (en) 2005-12-23
IL125081A0 (en) 1999-01-26
ES2244990T3 (es) 2005-12-16
EP0877803B1 (de) 2005-08-31
PT877803E (pt) 2005-11-30
DE69734096D1 (de) 2005-10-06
AU1526297A (en) 1997-08-01
JP2000502569A (ja) 2000-03-07
DK0877803T3 (da) 2005-09-19
EP0877803A1 (de) 1998-11-18
IL125081A (en) 2006-08-01
WO1997025424A1 (en) 1997-07-17

Similar Documents

Publication Publication Date Title
ATE303437T1 (de) Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
Cunningham et al. Molecular topography of the neural cell adhesion molecule N-CAM: surface orientation and location of sialic acid-rich and binding regions.
IL124831A0 (en) Ob protein derivatives having prolonged half-life
WO2001045746A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
EP1188830A4 (de) NEUES HäMOPOIETIN REZEPTORPROTEIN NR10
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
EP0662827A4 (de) Therapeutische und diagnostische verfahren und zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren.
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
TR200001079T2 (tr) Bisiklik kinaz inhibitörleri.
EP0683234A4 (de) ANTIKÖRPER GEGEN -g(b)-AMYLOID ODER DERIVATE DAVON UND SEINE VERWENDUNG.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ATE283916T1 (de) Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
CY1105654T1 (el) Εκλεκτικες ενωσεις για τον υποδοχεα της μελανοκορτινης 1
MXPA02008239A (es) Gen humano de la esquizofrenia.
IL109090A0 (en) Ptp-s31: a novel protein tyrosine phosphatase
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
TR200003624T2 (tr) Yeni poli(ADP-RİBOZ) polimeraz-genleri
ATE432349T1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
DE69737476D1 (de) Neuer galaninrezeptor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0877803

Country of ref document: EP

REN Ceased due to non-payment of the annual fee